Search Legislation

Commission Directive 2004/33/ECShow full title

Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)

 Help about what version

What Version

  • Latest available (Revised)
  • Original (As adopted by EU)
 Help about advanced features

Advanced Features

More Resources

 Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Status:

EU Directives are published on this site to aid cross referencing from UK legislation. Since IP completion day (31 December 2020 11.00 p.m.) no amendments have been applied to this version.

2.DEFERRAL CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTSU.K.

The tests and deferral periods indicated by an asterisk (*) are not required when the donation is used exclusively for plasma for fractionation.

2.1.Permanent deferral criteria for donors of allogeneic donationsU.K.

Cardiovascular diseaseProspective donors with active or past serious cardiovascular disease, except congenital abnormalities with complete cure
Central nervous system diseaseA history of serious CNS disease
Abnormal bleeding tendencyProspective donors who give a history of a coagulopathy
Repeated episodes of syncope, or a history of convulsionsOther than childhood convulsions or where at least three years have elapsed since the date the donor last took anticonvulsant medication without any recurrence of convulsions
Gastrointestinal, genitourinary, haematological, immunological, metabolic, renal, or respiratory system diseasesProspective donors with serious active, chronic, or relapsing disease
DiabetesIf being treated with insulin
Infectious diseasesHepatitis B, except for HBsAg-negative persons who are demonstrated to be immune
Hepatitis C
HIV-1/2
HTLV I/II
Babesiosis (*)
Kala Azar (visceral leishmaniasis) (*)
Trypanosomiasis cruzi (Chagas' disease) (*)
Malignant diseasesExcept in situ cancer with complete recovery
Transmissible spongiform encephalopathies (TSEs), (e.g. Creutzfeldt Jakob Disease, variant Creutzfeldt Jakob Disease)Persons who have a family history which places them at risk of developing a TSE, or persons who have received a corneal or dura mater graft, or who have been treated in the past with medicines made from human pituitary glands. For variant Creutzfeldt Jacob disease, further precautionary measures may be recommended.
Intravenous (IV) or intramuscular (IM) drug useAny history of non-prescribed IV or IM drug use, including body-building steroids or hormones
Xenotransplant recipients
Sexual behaviourPersons whose sexual behaviour puts them at high risk of acquiring severe infectious diseases that can be transmitted by blood

2.2.Temporary deferral criteria for donors of allogeneic donationsU.K.

2.2.1.InfectionsU.K.
Duration of deferral periodU.K.

After an infectious illness, prospective donors shall be deferred for at least two weeks following the date of full clinical recovery.

However, the following deferral periods shall apply for the infections listed in the table:

Brucellosis (*) 2 years following the date of full recovery
Osteomyelitis 2 years after confirmed cured
Q fever (*) 2 years following the date of confirmed cured
Syphilis (*) 1 year following the date of confirmed cured
Toxoplasmosis (*) 6 months following the date of clinical recovery
Tuberculosis 2 years following the date of confirmed cured
Rheumatic fever 2 years following the date of cessation of symptoms, unless evidence of chronic heart disease
Fever > °C 2 weeks following the date of cessation of symptoms
Flu-like illness 2 weeks after cessation of symptoms
Malaria (*)
individuals who have lived in a malarial area within the first five years of life

3 years following return from last visit to any endemic area, provided person remains symptom free;

may be reduced to 4 months if an immunologic or molecular genomic test is negative at each donation

individuals with a history of malaria

3 years following cessation of treatment and absence of symptoms.

Accept thereafter only if an immunologic or molecular genomic test is negative

asymptomatic visitors to endemic areas
6 months after leaving the endemic area unless an immunologic or molecular genomic test is negative
individuals with a history of undiagnosed febrile illness during or within six months of a visit to an endemic area

3 years following resolution of symptoms;

may be reduced to 4 months if an immunologic or molecular test is negative

West Nile Virus (WNV) (*) [F128 days after leaving a risk area of locally acquired West Nile Virus unless an individual Nucleic Acid Test (NAT) is negative]
2.2.2.Exposure to risk of acquiring a transfusion-transmissible infectionU.K.
  • Endoscopic examination using flexible instruments,

  • mucosal splash with blood or needlestick injury,

  • transfusion of blood components,

  • tissue or cell transplant of human origin,

  • major surgery,

  • tattoo or body piercing,

  • acupuncture unless performed by a qualified practitioner and with sterile single-use needles,

  • persons at risk due to close household contact with persons with hepatitis B.

Defer for 6 months, or for 4 months provided a NAT test for hepatitis C is negative
Persons whose behaviour or activity places them at risk of acquiring infectious diseases that may be transmitted by blood.Defer after cessation of risk behaviour for a period determined by the disease in question, and by the availability of appropriate tests
2.2.3.VaccinationU.K.
Attenuated viruses or bacteria 4 weeks
Inactivated/killed viruses, bacteria or rickettsiaeNo deferral if well
ToxoidsNo deferral if well
Hepatitis A or hepatitis B vaccinesNo deferral if well and if no exposure
Rabies

No deferral if well and if no exposure

If vaccination is given following exposure defer for one year

Tick-borne encephalitis vaccinesNo deferral if well and if no exposure
2.2.4.Other temporary deferralsU.K.
Pregnancy 6 months after delivery or termination, except in exceptional circumstances and at the discretion of a physician
Minor surgery 1 week
Dental treatment

Minor treatment by dentist or dental hygienist — defer until next day

(NB: Tooth extraction, root-filling and similar treatment is considered as minor surgery)

MedicationBased on the nature of the prescribed medicine, its mode of action and the disease being treated

2.3.Deferral for particular epidemiological situationsU.K.

Particular epidemiological situations (e.g. disease outbreaks)Deferral consistent with the epidemiological situation (These deferrals should be notified by the competent authority to the European Commission with a view to Community action)

2.4.Deferral criteria for donors of autologous donationsU.K.

Serious cardiac diseaseDepending on the clinical setting of the blood collection

Persons with or with a history of

  • hepatitis B, except for HBsAg-negative persons who are demonstrated to be immune

  • hepatitis C

  • HIV-1/2

  • HTLV I/II

Member States may, however, establish specific provisions for autologous donations by such persons
Active bacterial infection

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources